Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of radiotherapy plus anlotinib and PD-1 monoclonal antibody for unresectable advanced intrahepatic cholangiocarcinoma
ChiCTR2100046516Phase 2Recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Jun 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and PD-1 Monoclonal Antibody in intrahepatic cholangiocarcinoma (ICC), sponsored by Cancer Hospital of Guangxi Medical University. Primary endpoint: Progression-free survival. Started Jun 2021; status: recruiting.
02
Drugs
anlotinibPD-1 Monoclonal Antibody
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2100046516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046516.